Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant

Clinical Pharmacokinetics

Volumn 44, Issue 6, 2005, Pages 637-647

  Bergman, Arthur J ^a   Marbury, Thomas ^b   Fosbinder, Trisha ^c   Swan, Suzanne ^c   Hickey, Lisa ^a   Bradstreet, Thomas E ^a   Busillo, John ^a   Petty, Kevin J ^a   Aiyer, Kala Jyoti Viswanathan ^a   Constanzer, Marvin ^a   Huskey, Su Er W ^a   Majumdar, Anup ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c TOTAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT;

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; GEOMETRY; HEADACHE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; NAUSEA; PRIORITY JOURNAL; SEX DIFFERENCE; SOMNOLENCE; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ADULT; ANTIEMETICS; AREA UNDER CURVE; BLOOD PROTEINS; FEMALE; HALF-LIFE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MORPHOLINES; PROSPECTIVE STUDIES; PROTEIN BINDING; RECEPTORS, NEUROKININ-1; RENAL DIALYSIS;

EID: 22244474650     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544060-00005     Document Type: Article

References (19)

1. Tattersall FD, Rycroft W, Cumberbatch M, et al. The novel NK1 receptor antagonist MK-0869 (L-764-030) and its water soluble phosphoryl prodrug, L-758298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 2000; 39: 652-63
2. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction in cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754-030 Antiemetic Trials Group. N Engl J Med 1999; 340: 190-5
3. Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist: MK-069, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001; 19: 2971-94
4. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo controlled trial in Latin America. Cancer 2003; 97 (12): 2090-8
5. Balant LP, Dayer P, Fabre J. Consequences of renal insufficiency on the hepatic clearance of some drugs. Int J Clin Pharm Res 1983; 3 (6): 459-74
6. Yuan R, Venitz J. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. Int J Clin Pharmacol Res 2000; 38 (5): 245-53
7. Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels: implications for drug dosage regimens (Pt I). Clin Pharmacokinet 1990; 19: 147-59
8. Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels: implications for drug dosage regimens (Pt II). Clin Pharmacokinet 1990; 19: 218-29
9. Chapelsky MC, Thompson-Culkin K, Miller AK, et al. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharm 2003; 43 (3): 252-9
10. Muck W, Park S, Jager W, et al. The pharmacokinetics of cerivastatin in patients on chronic hemodialysis. Int J Clin Pharmacol Ther 2001; 39 (5): 192-8
11. Meier-Kriesche HU, Shaw LM, Korecka M, et al. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit 2000; 22 (1): 27-30
12. Martin DE, Chapelsky MC, Ilson B, et al. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment. J Clin Pharmacol 1998; 38 (2): 129-37
13. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Pharmacol Ther 2002; 71 (3): 115-21
14. Muirhead GJ, Wilner K, Colburn W, et al. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol 2002; 53 Suppl. 1: 21-30S
15. Legg B, Rowland M. Cyclosporin: measurement of fraction unbound in plasma. J Pharm Pharmacol 1987 Aug; 39 (8): 599-603
16. A double-blind, double-dummy, parallel, randomized, placebo-controlled study to investigate the pharmacokinetics, safety and tolerability of multiple doses of MK-0869 (125 and 375 mg/day) in healthy young subjects. West Point (PA): Merck & Co., Inc. (Data on file)
17. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97 (9): 2290-300
18. Lam YWF, Banerji S, Hatfield C, et al. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997; 32: 30-57
19. EMEND® product information [online]. Available from URL: http://www.emend.com/emend/shared/documents/pi.pdf [Accessed 2005 Apr 8]